Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Equity

4D Molecular Therapeutics (FDMT) Return on Sales: 2020-2024

Historic Return on Sales for 4D Molecular Therapeutics (FDMT) over the last 3 years, with Jun 2024 value amounting to -5.42%.

  • 4D Molecular Therapeutics' Return on Sales rose 4334.00% to -5.42% in Q2 2024 from the same period last year, while for Jun 2024 it was -5.42%, marking a year-over-year increase of 4334.00%. This contributed to the annual value of -4.86% for FY2023, which is 2949.00% up from last year.
  • As of Q2 2024, 4D Molecular Therapeutics' Return on Sales stood at -5.42%, which was down 6.28% from -5.10% recorded in Q1 2024.
  • 4D Molecular Therapeutics' Return on Sales' 5-year high stood at -2.26% during Q2 2021, with a 5-year trough of -53.30% in Q3 2022.
  • Over the past 3 years, 4D Molecular Therapeutics' median Return on Sales value was -19.89% (recorded in 2022), while the average stood at -24.64%.
  • As far as peak fluctuations go, 4D Molecular Therapeutics' Return on Sales slumped by 4,938bps in 2022, and later spiked by 4,894bps in 2023.
  • 4D Molecular Therapeutics' Return on Sales (Quarterly) stood at -4.15% in 2020, then rose by 20bps to -3.95% in 2021, then plummeted by 3,041bps to -34.35% in 2022, then skyrocketed by 2,950bps to -4.86% in 2023, then skyrocketed by 4,334bps to -5.42% in 2024.
  • Its Return on Sales was -5.42% in Q2 2024, compared to -5.10% in Q1 2024 and -4.86% in Q4 2023.